ScreenerHero
ABAB Science S.A.
EPA · FR · Healthcare · Drug Manufacturers - Specialty & Generic · ab-science.com
0.6920EUR-0.72%Mkt Cap: 72.61M $P/E: —

AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cance…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.24BUSDP/E 23.7
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.41BUSDP/E 20.1
ZOE
Zoetis Inc.
$29.37BUSDP/E 12.4
UTHR
United Therapeutics Corporation
$22.70BUSDP/E 19.0
VTRS
Viatris, Inc.
$18.66BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.39BUSDP/E 118.0
NBIX
Neurocrine Biosciences, Inc.
$15.81BUSDP/E 22.8
IPN
Ipsen S.A.
$14.67BUSDP/E 26.5
ELAN
Elanco Animal Health Incorporat
$12.24BUSD
KRK
Krka, d. d.
$8.57BUSDP/E 18.8
HIMS
Hims & Hers Health, Inc.
$7.25BUSD
LQDA
Liquidia Corporation
$6.74BUSDP/E 53.8
LNTH
Lantheus Holdings Inc
$6.56BUSDP/E 24.0
AMRX
Amneal Pharmaceuticals, Inc.
$6.23BUSDP/E 37.3
INDV
Indivior PLC Ordinary Shares
$4.61BUSDP/E 14.0
HIK
Hikma Pharmaceuticals PLC
$4.32BUSDP/E 12.5
AMLX
Amylyx Pharmaceuticals Inc. Common Stock
$4.30BUSD
SFZN
Siegfried Holding AG
$3.91BUSDP/E 20.4
ROVI
Laboratorios Farmaceuticos Rovi, S.A.
$3.34BUSDP/E 16.6
SUPN
Supernus Pharmaceuticals, Inc.
$2.82BUSD

Key Statistics

Company
Market Cap72.61M $
Enterprise Value65.16M $
Revenue (TTM)1.28M $
Gross Profit1.06M $
Net Income (TTM)-1.69M $
Revenue/Share0.0207 USD
Last Price0.6920 EUR
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees26
CountryFR
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINFR0010557264
Valuation
P/E (Trailing)—
P/E (Forward)-4.95
PEG—
EV/EBITDA80.47
EV/Revenue51.06
P/S56.98
P/B-2.95
EPS (TTM)-0.03
EPS (Forward)-0.14
52W Range
0.501016% of range1.680
52W High1.680 EUR
52W Low0.5010 EUR
Profitability
Gross Margin83.30%
Oper. Margin510.93%
EBITDA Margin63.46%
Profit Margin-132.62%
ROE9.05%
ROA-6.35%
Growth
Revenue Growth28.70%
Earnings Growth—
Cash Flow & Leverage
Operating CF-4.66M $
CapEx (TTM)306.52K $
FCF Margin143.03%
FCF Yield2.51%
Net Debt10.08M $
Net Debt/EBITDA12.44
Balance Sheet
Debt/Equity-1.10
Current Ratio0.96
Quick Ratio0.92
Book Value/Sh-0.2350 EUR
Cash/Share0.1390 EUR
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 EUR
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)4.485 EUR
Upside (mean)+548.1%
Target Range4.485 EUR – 4.485 EUR
# Analysts1
Ownership
Shares Out.96.53M
Float41.81M
Insiders47.71%
Institutions0.00%
Technical
SMA 500.7357 (-5.9%)
SMA 2001.091 (-36.6%)
Beta1.17
S&P 52W Chg18.16%
Avg Vol (30d)578.26K
Avg Vol (10d)1.08M
Technical Indicators
RSI (14)48.8
MACD0.0046
MACD Signal0.0002
MACD Hist.+0.0044
BB Upper0.8852 EUR
BB Middle0.6792 EUR
BB Lower0.4731 EUR
BB Width60.68%
ATR (14)0.0601 EUR
Vol Ratio (20d)0.63x